According to Inovio Pharmaceuticals, the decrease in the respective periods were mainly due to no revenue being recognised under the terminated Wyeth collaboration and licensing agreement as a result of the cancellation of the agreement in July 2009.
Inovio Pharma has posted a net loss of $1.41m for the third quarter 2010, or $0.01 loss per diluted share, compared to net loss of $2.95m, or $0.03 loss per diluted share, for the comparable period in 2009.
Inovio Pharma’s loss from operations was $4.56m, compared to $3.6m for the comparable period in 2009.
The company has posted a revenue of $3.78m for the nine months ended 30 September 2010, compared to $6.51m for the year ago period.
For the nine months ended 30 September 2010, Inovio Pharma posted a net loss of $11.32m, or $0.11 loss per diluted share, compared to $17.07m, or $0.26 loss per diluted share, for the year ago period.
The company’s loss from operations for the nine months ended 30 September 2010 was $13.94m, compared to $10.15m for the year ago period.